Acrivon Therapeutics, Inc. shareholders approved Approval of the Amendment and Restatement of the Company's 2022 Equity Incentive Plan.
“Votes were cast as follows: For Against Abstain Broker Non-Votes 20,546,400 3,757,400 104,757 6,928,436”
Acrivon Therapeutics, Inc. — fact timeline
Source-grounded facts extracted from Acrivon Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Acrivon Therapeutics, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm.
“Proposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm.”
Acrivon Therapeutics, Inc. shareholders approved Election of Michael Tomsicek, M.B.A. and Charles Baum, M.D., Ph.D. as Class I Directors.
“Votes were cast as follows: For Withheld Broker Non-Votes Michael Tomsicek, M.B.A. 24,020,408 1,229,385 6,087,200 Charles Baum, M.D., Ph.D. 23,657,074 1,592,719 6,087,200”
Acrivon Therapeutics, Inc. reported financial results for first quarter ended March 31, 2026.
“issued a press release announcing its financial results for the quarter ended March 31, 2026”
Acrivon Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income Net loss for the quarter and full year ended December 31, 2025 was $19.0 million and $77.9 million, respectively..
“Net loss for the quarter and full year ended December 31, 2025 was $19.0 million and $77.9 million, respectively.”
Acrivon Therapeutics, Inc. terminated OncoSignature Companion Diagnostic Agreement with Akoya Biosciences, Inc. (a wholly owned subsidiary of Quanterix Corporation) (effective 2026-02-25).
“On February 25, 2026, the Company and Akoya Biosciences, (“Akoya”) a wholly owned subsidiary of Quanterix Corporation (“Quanterix”), entered into a Termination and Transition Agreement pursuant to which they have mutually agreed to terminate (the “termination”) the OncoSignature Companion Diagnostic Agreement, dated June 17, 2022, by and between the Company and Akoya.”
Adam Levy was appointed as Chief Financial Officer at Acrivon Therapeutics, Inc..
“On March 14, 2025, Acrivon Therapeutics, Inc. (the “Company”) appointed Adam Levy, Ph.D., M.B.A., to the position of Chief Financial Officer, effective as of April 1, 2025 (the “Effective Date”).”
Rasmus Holm-Jorgensen resigned as Chief Financial Officer at Acrivon Therapeutics, Inc..
“On March 11, 2025, Rasmus Holm-Jorgensen, the Company’s Chief Financial Officer, notified the Company of his decision to step down from his position, effective April 1, 2025, for personal reasons to pursue another opportunity with a company based in Europe, allowing him to spend more time near his family.”
Acrivon Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income $16.5 million.
“Net loss for the quarter ended March 31, 2024 was $16.5 million compared to a net loss of $12.8 million for the same period in 2023.”
Acrivon Therapeutics, Inc. reported fourth quarter and full year ended December 31, 2023 results: net income $19.3 million and $60.4 million, respectively.
“Net loss for the quarter and full year ended December 31, 2023 was $19.3 million and $60.4 million, respectively.”
Santhosh Palani, Ph.D., CFA was appointed as director at Acrivon Therapeutics, Inc..
“On March 1, 2024, the Board of Directors of Acrivon Therapeutics, Inc. (the “Company”) appointed Santhosh Palani, Ph.D., CFA, as a director of the Company, effective March 4, 2024.”
Ivana Magovcevic-Liebisch was appointed as Director at Acrivon Therapeutics, Inc..
“On February 7, 2024, the Board of Directors of Acrivon Therapeutics, Inc. (the “Company”) appointed Ivana Magovcevic-Liebisch, Ph.D., J.D., as a director of the Company, effective February 8, 2024.”
Acrivon Therapeutics, Inc. amended OncoSignature Diagnostic Agreement with Akoya Biosciences, Inc. valued at $17,300,000 (effective 2023-12-04).
“On December 4, 2023, Acrivon Therapeutics, Inc. (the “Company”) entered into a Third Amendment to the OncoSignature Diagnostic Agreement (the “Third Amendment”) with Akoya Biosciences, Inc. (“Akoya”) for the development of the ACR-368 OncoSignature companion diagnostic test.”
Acrivon Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: net income $14.5 million.
“Net loss for the quarter ended September 30, 2023 was $14.5 million compared to a net loss of $9.2 million for the same period in 2022.”
Acrivon Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income $13.9 million.
“Net loss for the quarter ended June 30, 2023 was $13.9 million”
Acrivon Therapeutics, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-06-22 meeting.
“Proposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm The stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 by the following vote: For Against Abstain Broker Non-Votes 17,879,658 725 0 -”
Acrivon Therapeutics, Inc. shareholders approved Election of Class I Director at the 2023-06-22 meeting.
“Proposal One: Election of Michael Tomsicek, M.B.A. as a Class I Director Michael Tomsicek was elected to serve as a Class I director to hold office until the Company’s 2026 Annual Meeting of Stockholders and until the election and qualification of his successor. Votes were cast as follows: For Withheld Broker Non-Votes Michael Tomsicek, M.B.A. 17,527,002 226,168 127,213”
Acrivon Therapeutics, Inc. reported the quarter ended March 31, 2023 results: net income $12.8 million.
“Net loss for the quarter ended March 31, 2023 was $12.8 million”
Acrivon Therapeutics, Inc. reported preliminary financial results for the three months ended March 31, 2023.
“Acrivon Therapeutics, Inc. (the “Company”) will be updating its corporate presentation to include disclosure that the Company had $159.5 million of cash and marketable securities as of March 31, 2023 and to confirm its cash runway into at least the fourth quarter of 2024. Because the Company’s financial results for the three months ended March 31, 2023 have not been finalized or audited, the preliminary statement of the Company’s cash and marketable securities as of March 31, 2023 in this Item 2.02 is subject to change”
Acrivon Therapeutics, Inc. reported the full year ended December 31, 2022 results: net income $31.2 million.
“Net loss for the quarter and full year ended December 31, 2022 was $8.9 million and $31.2 million, respectively.”
Acrivon Therapeutics, Inc. reported the fourth quarter ended December 31, 2022 results: net income $8.9 million.
“Net loss for the quarter and full year ended December 31, 2022 was $8.9 million and $31.2 million, respectively.”
Acrivon Therapeutics, Inc.: Amended and Restated Bylaws adopted in connection with IPO closing (effective 2022-11-17).
“Effective as of November 17, 2022, the Company adopted Amended and Restated Bylaws (the “Restated Bylaws”) in connection with the closing of the IPO.”
Acrivon Therapeutics, Inc.: Amended and Restated Certificate of Incorporation filed in connection with IPO closing (effective 2022-11-17).
“On November 17, 2022, Acrivon Therapeutics, Inc. (the “Company”) filed an Amended and Restated Certificate of Incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the Company’s initial public offering of its common stock (the “IPO”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.